MX2014011825A - INHIBIDORES DE ISOXAZOL ß-LACTAMASA. - Google Patents
INHIBIDORES DE ISOXAZOL ß-LACTAMASA.Info
- Publication number
- MX2014011825A MX2014011825A MX2014011825A MX2014011825A MX2014011825A MX 2014011825 A MX2014011825 A MX 2014011825A MX 2014011825 A MX2014011825 A MX 2014011825A MX 2014011825 A MX2014011825 A MX 2014011825A MX 2014011825 A MX2014011825 A MX 2014011825A
- Authority
- MX
- Mexico
- Prior art keywords
- isoxazole
- lactamase inhibitors
- class
- compounds
- blis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se describen compuestos inhibidores de ß-lactamasa (BLIs), incluyendo compuestos que tienen actividad contra ß-lactamasas de la clase A, clase C o clase D. También se describen métodos para elaborar los BLIs, y usos de los compuestos en la preparación de composiciones farmacéuticas y aplicaciones antibacterianas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261618127P | 2012-03-30 | 2012-03-30 | |
US201361790248P | 2013-03-15 | 2013-03-15 | |
PCT/US2013/034589 WO2013149136A1 (en) | 2012-03-30 | 2013-03-29 | ISOXAZOLE β-LACTAMASE INHIBITORS |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2014011825A true MX2014011825A (es) | 2015-02-20 |
Family
ID=49261287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014011825A MX2014011825A (es) | 2012-03-30 | 2013-03-29 | INHIBIDORES DE ISOXAZOL ß-LACTAMASA. |
Country Status (14)
Country | Link |
---|---|
US (3) | US8927724B2 (es) |
EP (1) | EP2831069B1 (es) |
JP (1) | JP2015512419A (es) |
KR (1) | KR20150003777A (es) |
CN (1) | CN104334555A (es) |
AR (1) | AR090589A1 (es) |
AU (1) | AU2013237869A1 (es) |
CA (1) | CA2869051A1 (es) |
CO (1) | CO7091182A2 (es) |
IL (1) | IL234845A0 (es) |
MX (1) | MX2014011825A (es) |
SG (1) | SG11201406120SA (es) |
TW (1) | TW201343646A (es) |
WO (1) | WO2013149136A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201343645A (zh) * | 2012-03-30 | 2013-11-01 | Cubist Pharm Inc | 1,3,4-□二唑及1,3,4-噻二唑β-內醯胺酶抑制劑 |
US8969570B2 (en) * | 2012-03-30 | 2015-03-03 | Cubist Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
US20150038482A1 (en) * | 2012-03-30 | 2015-02-05 | Cubist Pharmaceuticals, Inc. | Isoxazole beta-lactamase inhibitors |
EP2831069B1 (en) | 2012-03-30 | 2017-07-12 | Merck Sharp & Dohme Corp. | Isoxazole beta-lactamase inhibitors |
US8916709B2 (en) * | 2012-03-30 | 2014-12-23 | Cubist Pharmaceuticals, Inc. | 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors |
AR090539A1 (es) | 2012-04-02 | 2014-11-19 | Astrazeneca Ab | COMPUESTOS INHIBIDORES DE b LACTAMASA |
US9120795B2 (en) | 2013-03-14 | 2015-09-01 | Cubist Pharmaceuticals, Inc. | Crystalline form of a β-lactamase inhibitor |
US9872906B2 (en) | 2013-03-15 | 2018-01-23 | Merck Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
US20140274997A1 (en) | 2013-03-15 | 2014-09-18 | Cubist Pharmaceuticals, Inc. | Cephalosporin pharmaceutical compositions |
US9120796B2 (en) | 2013-10-02 | 2015-09-01 | Cubist Pharmaceuticals, Inc. | B-lactamase inhibitor picoline salt |
WO2015066413A1 (en) | 2013-11-01 | 2015-05-07 | Novartis Ag | Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections |
IN2014MU00858A (es) * | 2014-03-14 | 2015-09-25 | Wockhardt Ltd | |
ES2719136T3 (es) | 2014-03-24 | 2019-07-08 | Novartis Ag | Compuestos orgánicos de monobactam para el tratamiento de infecciones bacterianas |
CN107108624B (zh) | 2014-11-17 | 2020-01-07 | 恩塔西斯治疗有限公司 | 用于治疗耐药性细菌感染的组合疗法 |
CA3000087A1 (en) | 2015-10-02 | 2017-04-06 | Legochem Biosciences, Inc. | Compositions and methods for inhibiting beta-lactamase |
CN105348173B (zh) * | 2015-12-02 | 2017-12-15 | 中山奕安泰医药科技有限公司 | 不对称催化氢化法合成阿维巴坦中间体5的方法 |
WO2017206947A1 (zh) * | 2016-06-03 | 2017-12-07 | 南京明德新药研发股份有限公司 | 新型β-内酰胺酶抑制剂 |
LT3512851T (lt) | 2016-09-16 | 2022-10-25 | Entasis Therapeutics Limited | Beta-laktamazės inhibitorių junginiai |
JOP20190061A1 (ar) | 2016-09-28 | 2019-03-26 | Novartis Ag | مثبطات بيتا-لاكتاماز |
CN108239089B (zh) * | 2016-12-27 | 2020-05-22 | 浙江医药股份有限公司新昌制药厂 | 一种阿维巴坦钠的合成方法 |
CN106699756B (zh) * | 2016-12-30 | 2019-10-29 | 淄博鑫泉医药技术服务有限公司 | β内酰胺酶抑制剂阿维巴坦的合成方法 |
ES2907858T3 (es) | 2017-05-08 | 2022-04-26 | Entasis Therapeutics Inc | Compuestos y métodos para el tratamiento de infecciones bacterianas |
US11180501B2 (en) | 2017-12-01 | 2021-11-23 | Qilu Pharmaceutical Co., Ltd. | Crystal form of β-lactamase inhibitor and preparation method therefor |
CN109970625B (zh) * | 2017-12-28 | 2021-02-26 | 新发药业有限公司 | 一种5r-苄氧氨基哌啶-2s-甲酸或其衍生物的制备方法 |
EP3744722A4 (en) * | 2018-01-25 | 2021-11-03 | Suzhou Sinovent Pharmaceuticals Co., Ltd. | Ss-LACTAMASE INHIBITOR AND ITS USE |
WO2019145784A2 (en) * | 2018-01-26 | 2019-08-01 | Legochem Biosciences, Inc. | Combination therapies for multi-drug resistant pathogens |
US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
US5039660A (en) | 1988-03-02 | 1991-08-13 | Endocon, Inc. | Partially fused peptide pellet |
FR2812635B1 (fr) | 2000-08-01 | 2002-10-11 | Aventis Pharma Sa | Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens |
US20130059774A1 (en) | 2000-08-01 | 2013-03-07 | Mahesh Vithalbhai Patel | Efflux pump inhibitors |
FR2835186B1 (fr) | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
WO2007129176A2 (en) | 2006-04-28 | 2007-11-15 | Wockhardt Ltd | Improvements in therapy for treating resistant bacterial infections |
AU2007300531A1 (en) | 2006-09-27 | 2008-04-03 | Merck Sharp & Dohme Corp. | Novel inhibitors of beta-lactamase |
FR2921060B1 (fr) | 2007-09-14 | 2012-06-15 | Novexel | Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires |
US20100120715A1 (en) | 2007-11-13 | 2010-05-13 | Burns Christopher J | Beta-lactamase inhibitors |
CA2712783C (en) | 2008-01-18 | 2013-03-19 | Timothy A. Blizzard | Beta-lactamase inhibitors |
FR2930553B1 (fr) | 2008-04-29 | 2010-05-21 | Novexel | Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases |
EP2921559A1 (en) | 2008-06-19 | 2015-09-23 | Astra Zeneca Holding France | Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases |
FR2936798B1 (fr) * | 2008-10-03 | 2012-09-28 | Novexel | Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens. |
WO2010118361A1 (en) | 2009-04-09 | 2010-10-14 | Sopharmia, Inc. | Beta lactamase inhibitors |
US20120053350A1 (en) | 2009-04-30 | 2012-03-01 | Ian Mangion | Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids |
FR2951171A1 (fr) | 2009-10-09 | 2011-04-15 | Novexel | Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation |
EP2536408A1 (en) | 2010-02-16 | 2012-12-26 | Wockhardt Research Centre | Efflux pump inhibitors |
US8772490B2 (en) | 2010-12-22 | 2014-07-08 | Meiji Seika Pharma Co., Ltd. | Optically active diazabicyclooctane derivatives and process for preparing the same |
DK2657234T3 (da) | 2010-12-22 | 2017-02-20 | Meiji Seika Pharma Co Ltd | Optisk aktivt diazabicyclooctanderivat og fremgangsmåde til fremstilling heraf |
EP2721005B1 (en) | 2011-06-17 | 2015-11-25 | AstraZeneca AB | Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
CA2842777C (en) | 2011-07-26 | 2015-12-29 | Wockhardt Limited | Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor |
BR112013032770A2 (pt) | 2011-07-26 | 2017-02-07 | Wockhardt Ltd | composições farmacêuticas compreendendo antibiótico beta-lactama, sulbactama e inibidor de beta-lactamase |
AU2012303693B2 (en) | 2011-08-30 | 2014-07-03 | Wockhardt Limited | 1,6- diazabicyclo [3,2,1] octan- 7 - one derivatives and their use in the treatment of bacterial infections |
AU2012310136B2 (en) | 2011-09-13 | 2016-07-07 | Wockhardt Limited | Nitrogen containing compounds and their use |
EP2831069B1 (en) | 2012-03-30 | 2017-07-12 | Merck Sharp & Dohme Corp. | Isoxazole beta-lactamase inhibitors |
US8916709B2 (en) * | 2012-03-30 | 2014-12-23 | Cubist Pharmaceuticals, Inc. | 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors |
TW201343645A (zh) * | 2012-03-30 | 2013-11-01 | Cubist Pharm Inc | 1,3,4-□二唑及1,3,4-噻二唑β-內醯胺酶抑制劑 |
US8969570B2 (en) * | 2012-03-30 | 2015-03-03 | Cubist Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
-
2013
- 2013-03-29 EP EP13769389.1A patent/EP2831069B1/en active Active
- 2013-03-29 TW TW102111615A patent/TW201343646A/zh unknown
- 2013-03-29 JP JP2015503634A patent/JP2015512419A/ja active Pending
- 2013-03-29 CN CN201380027972.3A patent/CN104334555A/zh active Pending
- 2013-03-29 CA CA2869051A patent/CA2869051A1/en not_active Abandoned
- 2013-03-29 KR KR1020147030476A patent/KR20150003777A/ko not_active Application Discontinuation
- 2013-03-29 WO PCT/US2013/034589 patent/WO2013149136A1/en active Application Filing
- 2013-03-29 SG SG11201406120SA patent/SG11201406120SA/en unknown
- 2013-03-29 US US13/853,498 patent/US8927724B2/en active Active
- 2013-03-29 MX MX2014011825A patent/MX2014011825A/es unknown
- 2013-03-29 AU AU2013237869A patent/AU2013237869A1/en not_active Abandoned
- 2013-04-03 AR ARP130101085A patent/AR090589A1/es unknown
-
2014
- 2014-04-23 US US14/260,184 patent/US20140323459A1/en not_active Abandoned
- 2014-09-28 IL IL234845A patent/IL234845A0/en unknown
- 2014-10-02 US US14/505,436 patent/US20150038479A1/en not_active Abandoned
- 2014-10-08 CO CO14222853A patent/CO7091182A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
IL234845A0 (en) | 2014-12-31 |
AU2013237869A1 (en) | 2014-10-23 |
US8927724B2 (en) | 2015-01-06 |
EP2831069A4 (en) | 2015-06-03 |
EP2831069A1 (en) | 2015-02-04 |
US20140323459A1 (en) | 2014-10-30 |
TW201343646A (zh) | 2013-11-01 |
EP2831069B1 (en) | 2017-07-12 |
CA2869051A1 (en) | 2013-10-03 |
CN104334555A (zh) | 2015-02-04 |
KR20150003777A (ko) | 2015-01-09 |
WO2013149136A1 (en) | 2013-10-03 |
JP2015512419A (ja) | 2015-04-27 |
SG11201406120SA (en) | 2014-10-30 |
US20130345190A1 (en) | 2013-12-26 |
US20150038479A1 (en) | 2015-02-05 |
AR090589A1 (es) | 2014-11-26 |
CO7091182A2 (es) | 2014-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2014011825A (es) | INHIBIDORES DE ISOXAZOL ß-LACTAMASA. | |
MX2014011827A (es) | Inhibidores de 1,3,4 - oxadiazol y 1,3,4 - tiadiazol b-lactamasa. | |
PH12017501306A1 (en) | Inhibitors of histone demethylases | |
UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
IL244597A0 (en) | Replication suppressors of influenza viruses, preparations containing them and their uses | |
IL238958B (en) | Glutaminase inhibitors, preparations containing them and their uses | |
GB201106750D0 (en) | Novel compounds | |
IL238959A0 (en) | Glutamase inhibitors, preparations containing them and their uses | |
IL220863A (en) | Oxazole derivatives of kinase inhibitors, medicinal preparations containing them and their uses | |
TN2014000138A1 (en) | Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases. | |
NZ720478A (en) | Autotaxin inhibitor compounds | |
CR20150224A (es) | Compuestos de cefem 2-sustituidos | |
IL235155B (en) | Arginase inhibitor compounds, compositions comprising same and uses thereof | |
MX2013008390A (es) | Preparacion de estructuras de metal-triazolato. | |
IN2014DN10670A (es) | ||
HK1206264A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3- | |
HK1198921A1 (en) | Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof dgla15-ohepa / 15-hetre | |
UA111744C2 (uk) | ЗАМІЩЕНІ ПІРИДОПІРАЗИНИ ЯК ІНГІБІТОРИ Syk | |
MX2014014832A (es) | Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa. | |
MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
WO2011113060A3 (en) | Antiviral compounds and methods of use thereof | |
EP3049389A4 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
EA201270728A1 (ru) | Пуриновые соединения | |
EP3049077A4 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
EP3039009A4 (en) | Mao-b selective inhibitor compounds, pharmaceutical compositions thereof and uses thereof |